EuropaBio Welcomes The Outcomes Of The High Level Pharmaceutical Forum And Calls For A Seamless Policy Framework To Support Patients And Research
EuropaBio welcomes the outcomes of the High Level Pharmaceutical Forum, which, for the first time in Europe, gathered all healthcare stakeholders to discuss the three key issues that dramatically slow down patient access to progress in medicine: the level of information available to patients, the understanding of the social, medical and economic value of innovative treatments and the identification of mechanisms to facilitate timely patient access to the right treatments.
More: continued here